Innovative Gene Therapy uniQure's focus on delivering potentially curative gene therapies for severe genetic diseases presents opportunities to target healthcare providers and clinics specializing in rare genetic conditions, offering cutting-edge treatment options.
Regulatory Advancements Recent progress with FDA and UK MHRA approvals and submissions for AMT-130 in Huntington's disease highlight the company's expanding pipeline; this opens doors for partnerships and sales efforts related to CNS gene therapies.
Financial Growth Potential Although uniQure reports quarterly losses, its substantial funding of 300 million USD underscores growth ambitions; there is potential to leverage this backing to forge collaborations with biotech investors and partners seeking innovative asset development.
Technology Platform Leverage uniQure's modular and validated technology platform can be marketed to research organizations and biotech firms interested in accelerating gene therapy development, creating opportunities for technology licensing or joint R&D initiatives.
Market Expansion Readiness With ongoing interactions with regulatory agencies and strategic submissions in key markets, uniQure is positioning itself for commercial launches, making it a potential partner for regional distributors and healthcare networks aiming to introduce novel gene therapies.
$100M$250M
$10B
$10B
$10B
$10B
$1B$10B
$250M$500M
$10B
$10B
$1B$10B
$50M$100M
uniQure uses 8 technology products and services including Adobe, SAS/GRAPH, AlphaSense, and more. Explore uniQure's tech stack below.
| uniQure Email Formats | Percentage |
| F.Last@uniqure.com | 94% |
| Last.First@uniqure.com | 4% |
| First.Last@uniqure.com | 1% |
| FLast@uniqure.com | 1% |
Biotechnology ResearchNorth Holland, Netherlands201-500 Employees
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
Company Overview
Media & News
Funding & FinancialsuniQure has raised a total of $300M of funding over 9 rounds. Their latest funding round was raised on Sep 25, 2025 in the amount of $300M.
uniQure's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsuniQure has raised a total of $300M of funding over 9 rounds. Their latest funding round was raised on Sep 25, 2025 in the amount of $300M.
uniQure's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com